OncoDaily will host The State of Oncology in 2026 With ZS, a virtual event bringing together oncology leaders, industry experts, and healthcare innovators to discuss the trends and challenges shaping the future of cancer care.
Supported by ZS, a global management consulting and technology firm with expertise across healthcare, life sciences, data, and analytics, the event will explore how the oncology landscape is evolving, from changing treatment approaches and emerging technologies to access, commercialization, and the growing role of artificial intelligence in cancer care.
Building on ZS’s State of Oncology in 2026 analysis, the discussion will examine the forces influencing oncology in 2026 and beyond, including shifts in disease burden, innovation strategies, healthcare delivery models, and opportunities to improve outcomes for patients worldwide.
The Focus: Understanding the Changing Oncology Landscape
Cancer care is entering a period of rapid transformation, driven by scientific advances, new therapeutic approaches, evolving healthcare systems, and increasingly complex market dynamics.
The State of Oncology in 2026 with ZS will explore key questions facing the oncology ecosystem, including:
- How are changes in cancer burden and unmet medical needs influencing oncology innovation?
- What opportunities exist in earlier-stage disease and underserved tumor types?
- How are companies adapting their portfolios and development strategies in an increasingly competitive landscape?
- How can healthcare systems improve access and ensure that advances in oncology reach more patients?
- What role will artificial intelligence and data-driven approaches play in the future of cancer research and care?
The discussion will highlight the importance of connecting scientific innovation with real-world implementation, considering not only the development of new therapies but also the broader systems required to deliver them effectively.
Meet the Speakers
Tom Neyarapally
Tom Neyarapally is the CEO and Co-Founder of Archetype Therapeutics, a biotechnology company focused on developing innovative cancer therapies. With experience spanning oncology drug development, biotechnology leadership, and healthcare innovation, he brings perspectives on how emerging therapeutic approaches can address unmet needs in cancer care.
Richa Poddar
Richa Poddar is Senior Vice President and Product Development & Commercialization Lead for cemsidomide at C4 Therapeutics. She brings extensive experience in oncology drug development, commercialization strategy, and translating scientific innovation into potential treatment options for patients with cancer.
Pavan Anne
Pavan Anne is a Principal at ZS and leads the firm’s Global Oncology and Precision Medicine Practice. His work focuses on oncology strategy, precision medicine, commercialization, diagnostics, and helping healthcare organizations navigate a rapidly evolving cancer landscape.
Matt Furlow
Matt Furlow is an Associate Partner at ZS and leads the company’s Radiopharmaceutical Center of Excellence. He brings expertise in oncology strategy, radiopharmaceutical innovation, and the evolving role of emerging modalities in cancer treatment.
Together, the speakers will share perspectives on how scientific innovation, business strategy, healthcare transformation, and emerging technologies are converging to shape the next era of oncology.
Continuing the OncoDaily–ZS Partnership
The event continues the collaboration between OncoDaily and ZS, following the successful OncoDaily Grand Rounds: AI in Oncology Edition held during ASCO 2026 in Chicago.
During the Grand Rounds, oncology experts, technology leaders, researchers, and healthcare professionals gathered to discuss the expanding role of artificial intelligence in cancer care and research. ZS served as the exclusive partner of the event, supporting a conversation focused on innovation, collaboration, and the future of oncology.
The continued partnership reflects a shared commitment to creating platforms where experts from different areas of the cancer ecosystem can exchange ideas and explore the challenges and opportunities shaping oncology.
ZS Continues Partnership with OncoDaily for The State of Oncology in 2026
Registration is open for all members of the oncology community interested in exploring the trends shaping cancer care in 2026 and beyond.
